ZLDPF Zealand Pharma A/S

Zealand Pharma conference call on February 19 at 2pm CET (8am ET) to present full year 2025 financial results

Zealand Pharma conference call on February 19 at 2pm CET (8am ET) to present full year 2025 financial results

Press Release – No. 3 / 2026

Zealand Pharma conference call on February 19 at 2pm CET (8am ET) to present full year 2025 financial results

Copenhagen, Denmark, February 12, 2026 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, announced that it will host a conference call on February 19, 2026, at 2:00 pm CET (8:00 am ET) following the announcement of financial results for the full year of 2025.

Participating in the call will be President and Chief Executive Officer, Adam Steensberg; Chief Financial Officer, Henriette Wennicke; and Chief Medical Officer, David Kendall. The presentation will be followed by a Q&A session.

The live listen-only audio webcast of the call and accompanying slide presentation will be accessible at . To receive telephone dial-in information and a unique personal access PIN, please register at .

Participants are advised to register for the call or webcast approximately 10 minutes before the start. A recording of the event will be available following the call on Zealand Pharma’s website at .

About Zealand Pharma A/S

Zealand Pharma A/S (Nasdaq: ZEAL) is a biotechnology company focused on advancing medicines for obesity and metabolic health. Combining more than 25 years of peptide R&D expertise with a proprietary data platform that leverages advanced data‑driven and AI/ML approaches, Zealand Pharma aims to lead a new era in obesity and metabolic health.

To date, more than ten Zealand Pharma‑invented drug candidates have entered clinical development, of which two products have reached the market and three candidates are in late-stage development. The Company has collaborations with global pharmaceutical and biotechnology partners for research, development, and commercialization.

Founded in 1998, Zealand Pharma is headquartered in Copenhagen, Denmark, with a U.S. presence in Boston, Massachusetts. Learn more at .

Contacts

Adam Lange (Investors)

Vice President, Investor Relations

Neshat Ahmadi (Investors)

Investor Relations Manager

Rachel James-Owens (Media)

Vice President, Corporate Communications & Media Relations

Zealand Pharma

Email:



EN
12/02/2026

Underlying

ZLDPFZealand Pharma A/S

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Zealand Pharma A/S

 PRESS RELEASE
Free
ZLDPF Zealand Pharma ...

Total number of shares and voting rights in Zealand Pharma as of March...

Total number of shares and voting rights in Zealand Pharma as of March 31, 2026 Company announcement – No. 6 / 2026 Total number of shares and voting rights in Zealand Pharma as of March 31, 2026 Copenhagen, Denmark, March 31, 2026 – Zealand Pharma A/S (“Zealand Pharma” or "the Company")  (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, today announces, in accordance with section 32 of the Danish Capital Markets Act, the total number of shares and voting rights in the Company at the end of a calendar month during which changes to its ...

March 31, 2026 1 EN
 PRESS RELEASE
Free
ZLDPF Zealand Pharma ...

Resolutions from Zealand Pharma's Annual General Meeting 2026

Resolutions from Zealand Pharma's Annual General Meeting 2026 Company announcement – No. 5 / 2026 Resolutions from Zealand Pharma's Annual General Meeting 2026 Copenhagen, Denmark, March 26, 2026 - Zealand Pharma A/S ("Zealand Pharma" or the “Company”) (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company transforming the future of metabolic health, today held its Annual General Meeting of 2026 as a partly electronic and partly physical general meeting (hybrid meeting). At the Annual General Meeting, all proposals presented to the Annual General Meeting were approved, save for the n...

March 26, 2026 1 EN
Jacob Mekhael ... (+3)
  • Jacob Mekhael
  • Kristof Samoy
  • Livio Luyten
UCB UCB S.A.
ROYAL VOPAK NV
ZLDPF ZEALAND PHARMA A/S
TINC TINC COMM. VA
03/25/26 March 25, 2026 1 EN
Jacob Mekhael
  • Jacob Mekhael
ZLDPF Zealand Pharma ...

Zealand Pharma Establishes Boston research hub

Zealand announced the establishment of a new research hub in Cambridge, Massachusetts, in the greater Boston area. The facility will serve as Zealand Pharma's primary US address and is expected to be operational from September 2026. Zealand Pharma's Cambridge hub will enhance the company's research platform through AI-driven drug discovery, advanced automation, and next-generation molecule creation, accelerating the translation of scientific insight into innovative medicines. The establishment o...

ZLDPF ZEALAND PHARMA A/S
03/25/26 March 25, 2026 1 EN
 PRESS RELEASE
Free
ZLDPF Zealand Pharma ...

Zealand Pharma Establishes U.S. Research Hub in Cambridge, Massachuset...

Zealand Pharma Establishes U.S. Research Hub in Cambridge, Massachusetts to Expand Drug Discovery Capabilities and Accelerate Medicine Creation Press release – No. 6 / 2026 Zealand Pharma Establishes U.S. Research Hub in Cambridge, Massachusetts to Expand Drug Discovery Capabilities and Accelerate Medicine Creation New research hub in Cambridge, Massachusetts, in the greater Boston area, expands global discovery capabilities, combining Zealand Pharma’s more than 25 years of expertise in peptides and metabolic health with Boston’s biotech innovation ecosystem. Copenhagen, Denmark and B...

March 24, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch